Recent commentary around Sarepta Therapeutics (SRPT) focuses on Elevidys, its gene therapy for Duchenne muscular dystrophy, with expectations of near term stabilization and renewed attention on the company’s siRNA pipeline and the evolving FDA stance.

The recent focus on Elevidys and Sarepta Therapeutics’ siRNA programs comes after a mixed share price record, with a 14.5% 7 day share price return and year to date share price performance down 17.74%, alongside a 3 year total shareholder return that has declined 84.63%. This suggests short term momentum has picked up while longer term returns remain weak.

If Elevidys and siRNA exposure has your attention, this can be a good moment to broaden your biotech watchlist with 40 healthcare AI stocks

With Sarepta Therapeutics shares down over the past year but still trading below some analyst price targets and intrinsic estimates, is the recent weakness pointing to an undervalued rare disease specialist, or is the market already pricing in future growth?

Most Popular Narrative: 19% Undervalued

The current $17.53 Sarepta Therapeutics share price sits meaningfully below the narrative fair value of $21.65, which is built around Elevidys, LGMD programs and siRNA optionality under a 7.8% discount rate.

The scheduled dissemination of additional safety and efficacy data for ELEVIDYS, and anticipated label updates for new patient populations, provides clear pathways to further demonstrate the therapy’s positive risk-benefit, likely enhancing long-term revenue drivers.

Curious what earnings path and profit margins would need to underpin that fair value? The narrative leans on shrinking top line, improving profitability and a richer future earnings multiple tied to Sarepta Therapeutics' gene therapy and RNA platforms.

Result: Fair Value of $21.65 (UNDERVALUED)

However, Sarepta Therapeutics still faces meaningful risks, including Elevidys safety concerns and administrative delays around gene therapy infusions that could constrain revenue and weaken the undervaluation case.

Another View: Sarepta Therapeutics Looks Expensive On Earnings

The most popular Sarepta Therapeutics narrative leans on a fair value of $21.65, yet the earnings based view tells a different story. On a P/E of 28.4x, Sarepta trades above the US Biotechs industry at 16.5x and above an estimated fair ratio of 6.5x, which points to valuation risk rather than clear upside. So which signal should carry more weight for you?

For a closer look at how this earnings based picture is built, including where the fair ratio could pull the P/E over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed sentiment around Sarepta Therapeutics leaves you undecided, take a moment to review the full picture for yourself and weigh both sides by checking the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Sarepta Therapeutics?

If Sarepta Therapeutics has sharpened your thinking, do not stop here. Broaden your opportunity set with a few targeted stock ideas pulled from the Simply Wall St screener.

• Target stronger long term compounding potential by reviewing companies flagged as screener containing 19 high quality undiscovered gems that may not yet be crowded trades.
• Prioritise sleep at night holdings by scanning 65 resilient stocks with low risk scores that score well on resilience and business stability.
• Strengthen your core portfolio by focusing on companies from the solid balance sheet and fundamentals stocks screener (48 results) that pair financial robustness with fundamental support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.